GlassScriptPhysician profile
Robert G Anding
NPI 1174526370
$756.62
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $50.08 · 2021: $94.20 · 2022: $242 · 2024: $31.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $254.50 | 2019-2022 | |
| Myovant Sciences INC. | $120.13 | 2022 | |
| Acessa Health INC. | $81.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.43 | 2019-2022 | |
| Coopersurgical, INC. | $36.08 | 2021 | |
| Renovia INC | $34.94 | 2019 | |
| Hologic Sales and Service, LLC | $31.57 | 2024 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Pfizer INC. | $25.08 | 2022 | |
| Aspira Women'S Health INC | $18.96 | 2022 | |
| Merck Sharp & Dohme LLC | $16.79 | 2021 | |
| Ascend Therapeutics US, LLC | $16.60 | 2019 | |
| Allergan, INC. | $15.90 | 2020 | |
| Astellas Pharma US INC | $14.54 | 2022 | |
| Lupin INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.